Clinuvel Pharmaceuticals Limited Share Price Deutsche Boerse AG
Stocks
UR9
AU000000CUV3
Pharmaceuticals
OTC Markets Traded|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.404 EUR | +10.41% |
|
+14.50% | -14.29% |
| 06-16 | Clinuvel Pharmaceuticals Advances US Listing Plan With SEC Filing for Nasdaq ADS Upgrade | MT |
| 04-28 | Clinuvel Pharmaceuticals plans level II ADR upgrade and Nasdaq listing as CUVL | RE |
| Market Cap | 501M 352M 307M 283M 266M 497M 33.16B 3.36B 1.31B 16.34B 1.32B 1.29B 56.64B | P/E 2026 * |
13.9x | P/E 2027 * | 13.1x |
|---|---|---|---|---|---|
| Enterprise Value | 247M 174M 151M 139M 131M 245M 16.36B 1.66B 644M 8.06B 652M 638M 27.94B | EV / Sales 2026 * |
2.48x | EV / Sales 2027 * | 2.04x |
| Free-Float |
83.79% | Yield 2026 * |
0.62% | Yield 2027 * | 0.81% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 day | +10.41% | ||
| 1 week | +14.50% | ||
| Current month | +13.21% | ||
| 1 month | +9.09% | ||
| 3 months | +4.90% | ||
| 6 months | -17.81% | ||
| Current year | -14.29% |
| 1 week | 5.4 |  | 6 |
| 1 month | 5.1 | | 6 |
| Current year | 5.1 | | 7.39 |
| 1 year | 5.1 | | 7.68 |
| 3 years | 4.8 | | 12.68 |
| 5 years | 4.8 | | 27 |
| 10 years | 2.61 | | 27 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 31/10/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 29/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 28/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 22/09/2019 |
| Chairman | - | 31/12/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +10.41% | +14.50% | - | - | 352M | |
| +0.33% | -0.25% | +18.76% | -22.11% | 62.05B | |
| 0.00% | -9.35% | +58.07% | +195.96% | 54.45B | |
| +4.38% | +43.00% | +43.00% | +43.00% | 43.09B | |
| +7.62% | +8.19% | -51.27% | -59.11% | 36.37B | |
| -1.05% | -1.69% | +55.35% | -33.92% | 29.02B | |
| +3.50% | +28.85% | +151.81% | -50.31% | 25.38B | |
| -0.78% | -8.91% | +43.87% | +55.34% | 19.62B | |
| +1.74% | +4.39% | -3.12% | +107.49% | 16.89B | |
| -0.05% | +0.41% | +56.32% | +94.95% | 15.93B | |
| Average | +2.61% | +3.20% | +41.42% | +36.81% | 33.64B | |
| Weighted average by Cap. | +1.85% | +2.21% | +37.91% | +36.83% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 99.46M 69.88M 60.88M 56.13M 52.79M 98.76M 6.59B 668M 259M 3.25B 262M 257M 11.25B | 105M 74.02M 64.5M 59.45M 55.92M 105M 6.98B 707M 275M 3.44B 278M 272M 11.92B |
| Net income | 35.97M 25.27M 22.02M 20.3M 19.09M 35.72M 2.38B 241M 93.78M 1.17B 94.85M 92.82M 4.07B | 38.2M 26.84M 23.38M 21.56M 20.28M 37.93M 2.53B 256M 99.6M 1.25B 101M 98.58M 4.32B |
| Net Debt | -254M -178M -155M -143M -135M -252M -16.8B -1.7B -661M -8.28B -669M -655M -28.69B | -286M -201M -175M -161M -152M -284M -18.94B -1.92B -746M -9.33B -754M -738M -32.35B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/06/26 | 6.000 € | +3.45% | 0 |
| 18/06/26 | 5.800 € | -0.03% | 0 |
| 17/06/26 | 5.802 € | +7.44% | 562 |
| 16/06/26 | 5.400 € | -1.85% | 35 |
| 15/06/26 | 5.502 € | +5.00% | 0 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
- UR9 Stock
Select your edition
All financial news and data tailored to specific country editions
